CA2634945A1 - Soluble human m-csf receptor and uses thereof - Google Patents
Soluble human m-csf receptor and uses thereof Download PDFInfo
- Publication number
- CA2634945A1 CA2634945A1 CA002634945A CA2634945A CA2634945A1 CA 2634945 A1 CA2634945 A1 CA 2634945A1 CA 002634945 A CA002634945 A CA 002634945A CA 2634945 A CA2634945 A CA 2634945A CA 2634945 A1 CA2634945 A1 CA 2634945A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- soluble
- csf
- csfr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/53—Colony-stimulating factor [CSF]
- G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75321805P | 2005-12-22 | 2005-12-22 | |
| US60/753,218 | 2005-12-22 | ||
| PCT/US2006/048879 WO2007120252A2 (en) | 2005-12-22 | 2006-12-21 | Soluble human m-csf receptor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2634945A1 true CA2634945A1 (en) | 2007-10-25 |
Family
ID=38609972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002634945A Abandoned CA2634945A1 (en) | 2005-12-22 | 2006-12-21 | Soluble human m-csf receptor and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20100099123A1 (https=) |
| EP (1) | EP1977238B1 (https=) |
| JP (2) | JP2009521685A (https=) |
| KR (1) | KR101358600B1 (https=) |
| CN (1) | CN101379400A (https=) |
| AU (1) | AU2006342119B8 (https=) |
| CA (1) | CA2634945A1 (https=) |
| WO (1) | WO2007120252A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
| WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
| EP2950098A1 (en) * | 2009-07-14 | 2015-12-02 | National Institute of Advanced Industrial Science and Technology | Glycan markers as measure of disease state of hepatic diseases |
| RU2427323C1 (ru) * | 2010-02-25 | 2011-08-27 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" | Способ прогнозирования генерализации процесса при злокачественных опухолях костей |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| ES2442991B1 (es) * | 2012-08-14 | 2014-11-25 | Fundación Md Anderson International España | Método para el diagnóstico y/o pronóstico de linfomas |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| AU2015280362B2 (en) | 2014-06-23 | 2021-03-04 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
| PT3212670T (pt) | 2014-10-29 | 2021-02-15 | Bristol Myers Squibb Co | Terapêutica de combinação para cancro |
| EA201791421A1 (ru) | 2014-12-22 | 2017-10-31 | Файв Прайм Терапьютикс, Инк. | Антитела против csf1r для лечения pvns |
| BR112017020952A2 (pt) | 2015-04-13 | 2018-07-10 | Five Prime Therapeutics Inc | método de tratamento de câncer, composição e uso da composição |
| SG11202001606XA (en) | 2017-09-13 | 2020-03-30 | Five Prime Therapeutics Inc | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| AU2728588A (en) * | 1987-10-23 | 1989-05-23 | Genetics Institute Inc. | Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene |
| JPH0967400A (ja) * | 1995-08-31 | 1997-03-11 | Toray Ind Inc | モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用 |
| US6610484B1 (en) * | 1999-01-26 | 2003-08-26 | Cytyc Health Corporation | Identifying material from a breast duct |
| WO2004045532A2 (en) * | 2002-11-15 | 2004-06-03 | Chiron Corporation | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| US20040209937A1 (en) * | 2003-02-24 | 2004-10-21 | Sugen, Inc. | Treatment of excessive osteolysis with indolinone compounds |
-
2006
- 2006-12-21 CN CNA2006800519125A patent/CN101379400A/zh active Pending
- 2006-12-21 WO PCT/US2006/048879 patent/WO2007120252A2/en not_active Ceased
- 2006-12-21 AU AU2006342119A patent/AU2006342119B8/en active Active
- 2006-12-21 CA CA002634945A patent/CA2634945A1/en not_active Abandoned
- 2006-12-21 KR KR1020087017904A patent/KR101358600B1/ko active Active
- 2006-12-21 EP EP06850597.3A patent/EP1977238B1/en active Active
- 2006-12-21 JP JP2008547568A patent/JP2009521685A/ja not_active Withdrawn
- 2006-12-21 US US12/158,877 patent/US20100099123A1/en not_active Abandoned
-
2012
- 2012-02-29 JP JP2012043540A patent/JP2012108155A/ja active Pending
-
2013
- 2013-02-20 US US13/771,395 patent/US20140030738A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009521685A (ja) | 2009-06-04 |
| AU2006342119A1 (en) | 2007-10-25 |
| JP2012108155A (ja) | 2012-06-07 |
| WO2007120252A3 (en) | 2008-10-09 |
| US20140030738A1 (en) | 2014-01-30 |
| EP1977238A2 (en) | 2008-10-08 |
| KR20080085054A (ko) | 2008-09-22 |
| AU2006342119B8 (en) | 2013-05-09 |
| AU2006342119A8 (en) | 2013-05-09 |
| AU2006342119B2 (en) | 2013-01-10 |
| EP1977238B1 (en) | 2016-09-28 |
| CN101379400A (zh) | 2009-03-04 |
| KR101358600B1 (ko) | 2014-02-06 |
| WO2007120252A2 (en) | 2007-10-25 |
| US20100099123A1 (en) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140030738A1 (en) | Soluble human m-csf receptor and uses thereof | |
| KR102057438B1 (ko) | 엽산 수용체 알파-발현 암에 대한 진단 및 예후 마커로서의 엽산 수용체 알파 | |
| CA2425761C (en) | Non-invasive enzyme screen for tissue remodelling-associated conditions | |
| EP2564202B1 (en) | Methods for detecting anti-drug antibodies | |
| US20210230704A1 (en) | Compositions and methods for detecting pancreatic cancer | |
| WO2011031517A1 (en) | Method and assay for determining fas expression | |
| KR20110022621A (ko) | ＩｇＡ 신증의 검사 방법 및 검사 키트 | |
| US20250172572A1 (en) | Noninvasive method to quantify kidney function and functional decline | |
| RU2671578C2 (ru) | Способ прогнозирования риска возникновения рака или диагностирования рака у женщины | |
| CN108139404A (zh) | 特异性地识别、结合活性结构的REIC/Dkk-3蛋白的抗体、以及使用该抗REIC/Dkk-3抗体的癌治疗的监测 | |
| JP2018519525A (ja) | ＩｇＧ４κ／λハイブリッド抗体の検出によってＩｇＧ４関連疾患を検出またはモニタリングする方法 | |
| AU2012261609A1 (en) | Soluble human M-CSF receptor and uses thereof | |
| MX2008007881A (es) | Receptor m-csf humano soluble y usos del mismo | |
| CN110687284B (zh) | 检测血清中six2自身抗体的试剂的应用 | |
| CN103558391A (zh) | 可溶性人m-csf受体及其应用 | |
| CN119667163B (zh) | Il-1r2在鉴定对象免疫状态中的应用 | |
| CN102597772B (zh) | 5.9kDa肽的免疫学测定方法 | |
| JP2008537101A (ja) | 薬物応答を予測するための前立腺特異的抗原の使用 | |
| WO2005060627A2 (en) | Methods of assessing the risk of non-traumatic bone fracture | |
| WO2014023819A1 (en) | Methods for predicting the survival time of a patient suffering from a glioblastoma | |
| JPWO2020101039A1 (ja) | 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果判定 | |
| US20120301879A1 (en) | Novel use of ca-125 | |
| JP2002541214A5 (https=) | ||
| HK1212762B (zh) | 预测女性对象患癌症风险或诊断其癌症的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDC | Discontinued application reinstated | ||
| FZDE | Discontinued |
Effective date: 20161221 |